Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 321

1.

Synergistic induction of apoptosis by polo-like kinase 1 inhibitor and microtubule-interfering drugs in Ewing sarcoma cells.

Weiß L, Hugle M, Romero S, Fulda S.

Int J Cancer. 2015 Aug 11. doi: 10.1002/ijc.29725. [Epub ahead of print]

PMID:
26260582
2.

Oncogenic RAS Mutants Confer Resistance of RMS13 Rhabdomyosarcoma Cells to Oxidative Stress-Induced Ferroptotic Cell Death.

Schott C, Graab U, Cuvelier N, Hahn H, Fulda S.

Front Oncol. 2015 Jun 22;5:131. doi: 10.3389/fonc.2015.00131. eCollection 2015.

3.

Smac Mimetic-Induced Upregulation of CCL2/MCP-1 Triggers Migration and Invasion of Glioblastoma Cells and Influences the Tumor Microenvironment in a Paracrine Manner.

Lindemann C, Marschall V, Weigert A, Klingebiel T, Fulda S.

Neoplasia. 2015 Jun;17(6):481-9. doi: 10.1016/j.neo.2015.05.002.

4.

Hedgehog Inhibitors in Rhabdomyosarcoma: A Comparison of Four Compounds and Responsiveness of Four Cell Lines.

Ridzewski R, Rettberg D, Dittmann K, Cuvelier N, Fulda S, Hahn H.

Front Oncol. 2015 Jun 8;5:130. doi: 10.3389/fonc.2015.00130. eCollection 2015.

5.

Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia.

Opel D, Schnaiter A, Dodier D, Jovanovic M, Gerhardinger A, Idler I, Mertens D, Bullinger L, Stilgenbauer S, Fulda S.

Int J Cancer. 2015 Jun 20. doi: 10.1002/ijc.29650. [Epub ahead of print]

PMID:
26096065
6.

Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines.

Unland R, Clemens D, Heinicke U, Potratz JC, Hotfilder M, Fulda S, Wardelmann E, Frühwald MC, Dirksen U.

Anticancer Drugs. 2015 Sep;26(8):843-51. doi: 10.1097/CAD.0000000000000256.

PMID:
26053276
7.

Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis.

Czaplinski S, Hugle M, Stiehl V, Fulda S.

Oncotarget. 2015 May 14. [Epub ahead of print]

8.

Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells.

Steinwascher S, Nugues AL, Schoeneberger H, Fulda S.

Cancer Lett. 2015 Sep 28;366(1):32-43. doi: 10.1016/j.canlet.2015.05.020. Epub 2015 May 28.

PMID:
26028172
9.

Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs.

Hugle M, Belz K, Fulda S.

Cell Death Differ. 2015 May 29. doi: 10.1038/cdd.2015.59. [Epub ahead of print]

PMID:
26024389
10.

Targeting IAP proteins in combination with radiotherapy.

Fulda S.

Radiat Oncol. 2015 Apr 26;10(1):105. doi: 10.1186/s13014-015-0399-3.

11.

Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.

Stehle A, Hugle M, Fulda S.

Cancer Lett. 2015 Aug 28;365(1):37-46. doi: 10.1016/j.canlet.2015.04.011. Epub 2015 Apr 23.

PMID:
25917079
12.

Smac mimetic and oleanolic acid synergize to induce cell death in human hepatocellular carcinoma cells.

Liese J, Abhari BA, Fulda S.

Cancer Lett. 2015 Aug 28;365(1):47-56. doi: 10.1016/j.canlet.2015.04.018. Epub 2015 Apr 23.

PMID:
25917078
13.

Identification of RIP1 as a critical mediator of Smac mimetic-mediated sensitization of glioblastoma cells for Drozitumab-induced apoptosis.

Cristofanon S, Abhari BA, Krueger M, Tchoghandjian A, Momma S, Calaminus C, Vucic D, Pichler BJ, Fulda S.

Cell Death Dis. 2015 Apr 16;6:e1724. doi: 10.1038/cddis.2014.592.

PMID:
25880091
14.

Reactive oxygen species regulate Smac mimetic/TNFα-induced necroptotic signaling and cell death.

Schenk B, Fulda S.

Oncogene. 2015 Apr 13. doi: 10.1038/onc.2015.35. [Epub ahead of print]

PMID:
25867066
15.

Reduced sleep quality and depression associate with decreased quality of life in patients with pituitary adenomas.

Leistner SM, Klotsche J, Dimopoulou C, Athanasoulia AP, Roemmler-Zehrer J, Pieper L, Schopohl J, Wittchen HU, Stalla GK, Fulda S, Sievers C.

Eur J Endocrinol. 2015 Jun;172(6):733-43. doi: 10.1530/EJE-14-0941. Epub 2015 Mar 19.

PMID:
25792374
16.

NIK is required for NF-κB-mediated induction of BAG3 upon inhibition of constitutive protein degradation pathways.

Rapino F, Abhari BA, Jung M, Fulda S.

Cell Death Dis. 2015 Mar 12;6:e1692. doi: 10.1038/cddis.2014.584.

17.
18.

Safety and tolerability of TRAIL receptor agonists in cancer treatment.

Fulda S.

Eur J Clin Pharmacol. 2015 May;71(5):525-7. doi: 10.1007/s00228-015-1823-1. Epub 2015 Feb 24.

PMID:
25704217
19.

Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo.

Gajer JM, Furdas SD, Gründer A, Gothwal M, Heinicke U, Keller K, Colland F, Fulda S, Pahl HL, Fichtner I, Sippl W, Jung M.

Oncogenesis. 2015 Feb 9;4:e137. doi: 10.1038/oncsis.2014.51.

20.

Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.

Michaelis M, Agha B, Rothweiler F, Löschmann N, Voges Y, Mittelbronn M, Starzetz T, Harter PN, Abhari BA, Fulda S, Westermann F, Riecken K, Spek S, Langer K, Wiese M, Dirks WG, Zehner R, Cinatl J, Wass MN, Cinatl J Jr.

Sci Rep. 2015 Feb 3;5:8202. doi: 10.1038/srep08202.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk